Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Histórico de Dividendos BPMUF
Análise de Dividendos BPMUF
Max Ratio
–Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Basilea Pharmaceutica AG
BPMUFBasilea Pharmaceutica AG engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis. It also develops Fosmanogepix, an antifungal drug for the treatment of Candidemia, which is in Phase II clinical trials; BAL2062 for invasive mold infections, which is in Phase I of clinical trials; and BAL2420, an antibiotics to treat severe Enterobacteriaceae infections. In addition, the company provides Zevtera, an antibiotic for the treatment of pneumonia, as well as develop for the treatment of Staphylococcus aureus bacteremia, acute bacterial skin, and skin structure infections. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland. Address: Hegenheimermattweg 167b, Allschwil, Switzerland, 4123
Analytics
Preço Alvo de Wall Street
61.53 CHFRácio P/E
8.01Rendimento de dividendos
–Relatório BPMUF
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |